Loading organizations...
Loading organizations...
Materna Medical is a technology company.
Materna Medical engineers medical devices to address critical challenges in women's pelvic health. Products include Milli, developed for vaginal muscle tightness and painful intercourse, and Materna Prep, an investigational device aimed at preventing childbirth injuries. These solutions offer targeted physical support and therapy for various pelvic floor conditions, enhancing patient outcomes through innovative design and medical focus.
The company originated from a clear understanding of underserved needs in women's health. Materna Medical, a female-led organization, was founded on the insight that effective, non-invasive solutions were critically lacking for common, yet often overlooked, conditions impacting women. This fundamental perspective drove the company to specialize in dedicated advancements for this specific medical field.
Materna Medical serves women experiencing diverse pelvic health issues alongside the clinicians who provide their care. Its vision is to advance women's health through clinically-backed, innovative products. These offerings empower individuals to protect and restore their pelvic well-being, broadening access to effective care and significantly improving the quality of life for its users.
Materna Medical has raised $40.0M across 2 funding rounds.
Materna Medical has raised $40.0M in total across 2 funding rounds.
Materna Medical is a Mountain View, California-based medtech company developing innovative OBGYN platform technologies to address unmet needs in women's pelvic health, targeting a market estimated at $25 billion.[1][2][4][6] Its first product, the FDA-cleared Milli Vaginal Dilator with Vibration, treats vaginal muscle tightness (vaginismus) and painful intercourse (dyspareunia) for conditions like menopause, postpartum recovery, cancer side effects, and sexual assault, serving over 5,000 users via direct-to-consumer sales and healthcare referrals.[2][3][5][7] The company serves women facing common pelvic conditions and healthcare providers, solving under-treated issues like pelvic floor injuries affecting 10% of vaginal births annually, which contribute to pelvic organ prolapse.[2][7] Growth momentum includes a $10M Series A2 in 2021, $20M Series B2 advised by Wilson Sonsini, completion of pivotal EASE trial enrollment across 20 U.S. hospitals, De Novo FDA filing for its pipeline product Ellora, and ongoing POMPOM study data presented in 2025.[2][3][4][5]
Materna Medical emerged from Stanford University’s Biodesign program, where its proprietary pelvic floor technologies were developed, and it continues as a Company-In-Residence at Fogarty Innovation in Silicon Valley.[3][6] Founded in 2010, the company launched its first product, Milli, in 2019 after receiving FDA 510(k) clearance in December 2021 for vaginismus and dyspareunia relief; early traction built through commercial manufacturing and partnerships, amassing over 5,000 users.[2][3][5][7] Pivotal moments include a $2.2M NIH grant funding initial biomechanical research with University of Michigan experts, a $10M Series A2 in 2021 to support the EASE pivotal trial for Prep/Ellora (completed enrollment by 2022 across 15+ sites), and a De Novo FDA submission as a novel device without predicates.[2][3] Leadership from CEO Tracy MacNeal (engineer with Duke MBA and MedTech exits), COO Kelly Ashfield (device launch expert), and medical advisors like Edward Evantash, MD, and Helai Hesham, MD, has driven evolution from at-home dilators to labor-delivery innovations.[6]
Materna rides the wave of women's health tech innovation, targeting the vastly underserved $25B pelvic health market amid rising focus on gender-specific medtech, postpartum recovery, and preventive OBGYN care.[1][2][4][6] Timing aligns with post-pandemic emphasis on at-home devices, FDA pathways for novel tech (De Novo), and hospital demands for birthing innovations to attract patients—positioning Materna alongside rarities like Alydia Health in labor-delivery commercialization.[2] Market forces include high prevalence (300,000+ annual U.S. pelvic floor detachments), reimbursement opportunities, and investor interest (Series funding from Wavemaker 360, Wilson Sonsini), amplified by 7 patents in gynaecology, childbirth, and related areas.[2][3][4][5] It influences the ecosystem by validating pelvic devices in ESP matrices, driving data from trials like EASE/POMPOM, and normalizing proactive pelvic protection, potentially reducing prolapse and enhancing maternal outcomes.[2][5][7]
Materna Medical is poised for commercialization of Ellora within 1-2 years post-De Novo feedback, unlocking hospital adoption and revenue alongside Milli's established DTC base, with pipeline expansion in OBGYN platform tech.[2][7] Trends like AI-biomechanics integration, global women's health funding, and value-based care (e.g., reduced C-sections) will accelerate growth, evolving its influence from niche disruptor to standard-of-care leader in pelvic health.[2][3][6] As it scales from Stanford roots to $25B market capture, Materna exemplifies medtech's power to transform women's everyday pelvic challenges into preventable triumphs.[1][4]
Materna Medical has raised $40.0M in total across 2 funding rounds.
Materna Medical's investors include Ariella P. Golomb, MD, Band of Angels, Golden Seeds, Houston Angel Network, Kimera, Wavemaker Three-Sixty Health, Women's Venture Capital Fund.
Materna Medical has raised $40.0M across 2 funding rounds. Most recently, it raised $20.0M Series B in May 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 23, 2024 | $20.0M Series B | Ariella P. Golomb, MD | Band of Angels, Golden Seeds, Houston Angel Network, Kimera, Wavemaker Three-Sixty Health, Women's Venture Capital Fund |
| Aug 8, 2022 | $20.0M Series B | Ariella P. Golomb, MD | Kimera, Wavemaker Three-Sixty Health |